Off the shelf T cell therapies for hematologic malignancies
- 1 June 2018
- journal article
- research article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 31 (2) , 166-175
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transferGene Therapy, 2014
- Adoptive Therapy With Chimeric Antigen Receptor–Modified T Cells of Defined Subset CompositionThe Cancer Journal, 2014
- Simplified process for the production of anti–CD19-CAR–engineered T cellsCytotherapy, 2013
- T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemiaBlood, 2013
- Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patientsCancer Immunology, Immunotherapy, 2013
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic LeukemiaScience Translational Medicine, 2013
- Multiplex Genome Engineering Using CRISPR/Cas SystemsScience, 2013
- A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCRBlood, 2012
- piggyBac Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage MalignanciesHuman Gene Therapy, 2010